Bei Akademie registrieren
Johnson & Johnson, US4781601046

Johnson & Johnson reports data. Johnson & Johnson stock trades 0.14 percent above close

Published on 10/25/2026 at 17:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson stock costs EUR 235.38 in weekend trading on October 25, 2026 versus EUR 235.05 at Xetra close. Phase 1 data show 75 percent responses.

Clinical data and next session

  • Johnson & Johnson reported a 75 percent tumor response rate on October 25, 2026.
  • Johnson & Johnson stock traded at EUR 235.38 at 5:00 p.m. CET on October 25, 2026, 0.14 percent above the October 23, 2026 Xetra close.
  • The next Xetra session is scheduled for October 26, 2026.
Pop art comic book illustration of a large beige adhesive bandage roll centered on a halftone dot background in cyan and magenta, bold black comic outlines, yellow starburst and red lightning bolt elements radiating outward, flat primary colors of red blu
Johnson Consumer Health im Pop Art Stil, US4781601046 Pflasterrolle mit Halftone und Comic Outlines, Illustration mit AI erstellt.

Johnson & Johnson reported Phase 1 data for JNJ-6143 on October 25, 2026, with a 75 percent complete or partial tumor response rate among 16 patients with measurable disease in the 50-milligram cohort, according to the company’s investor-relations release. At 5:00 p.m. CET, Johnson & Johnson stock traded at EUR 235.38 in weekend trading at Lang & Schwarz, 0.14 percent above the Xetra close of October 23, 2026 at EUR 235.05.

Market context: Market report S&P 500.

Weekend trading

The Lang & Schwarz price was EUR 235.38 at 5:00 p.m. CET on October 25, 2026. The reference level was the Xetra close of October 23, 2026 at EUR 235.05, putting the weekend-trading price 0.14 percent higher. The bid was EUR 235.15 and the ask was EUR 235.60. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Johnson & Johnson stock.

Clinical development

The company said 77 percent of 38 patients receiving the 50-milligram once-daily dose had a confirmed reduction of at least 50 percent in prostate-specific antigen, while 48 percent had reductions of at least 90 percent. Johnson & Johnson said the dose will advance into further clinical development, including a Phase 2 study in metastatic prostate cancer. These details were reported in the company’s October 25, 2026 release.

Next Xetra session

The next Xetra session is scheduled for October 26, 2026.

Disclaimer...
en | US4781601046 | JOHNSON & JOHNSON | boerse | 70409570 | bgmi